{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-091219","form_type":"8-K","ticker":"CRBP","cik":"0001595097","company_name":"Corbus Pharmaceuticals Holdings, Inc.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.697540+00:00","generated_at":"2026-05-31T12:16:43.046338+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Corbus Pharma Q2 loss $10M; CRB-701 shows 44% ORR in mUC; cash runway through Q3 2027","bullets":["Net loss of $10.0M ($0.90 per diluted share) for Q2 2024, compared to net loss of $8.8M ($2.05 per share) in Q2 2023.","Cash and investments of $147M at June 30; raised $28.8M additional through Aug 1; cash runway extended through Q3 2027.","CRB-701 Phase 1 data: 44% ORR and 78% DCR in metastatic urothelial cancer; 43% ORR and 86% DCR in cervical cancer at doses ≥1.2mg/kg.","US/EU Phase 1 dose escalation for CRB-701 commenced April 2024; completion expected Q4 2024; data presentation Q1 2025.","CRB-913 Phase 1 start expected Q1 2025; CRB-601 Phase 1 start expected Q4 2024; both pre-clinical data support advancement."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-091219","json":"https://secwatch.observer/filing/0000950170-24-091219.json","markdown":"https://secwatch.observer/filing/0000950170-24-091219.md","text":"https://secwatch.observer/filing/0000950170-24-091219.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595097/000095017024091219/0000950170-24-091219-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595097/000095017024091219/crbp-20240806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:16:43.046338+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}